A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy.

Trial Profile

A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2015 Primary endpoint has not been met. (PFS proportion achieved with STA-9090 in men with CRPC who have received prior docetaxel based therapy), as per results published in the Investigational New Drugs.
    • 18 Nov 2015 Study was terminated early due to inadequate response, as per results published in the Investigational New Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top